文献速递肝病

代谢功能障碍相关脂肪性肝炎的联合治疗:挑战与机遇

Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities.
PubMed 文献 · Gut · 2026-03-06

本文综述代谢功能障碍相关脂肪性肝炎(MASH)多靶点联合治疗。MASH是肥胖、胰岛素抵抗和心血管代谢共病背景下的多因素代谢性肝病,单靶点单药治疗对肝纤维化和全身代谢改善有限。联合策略可调节互补致病过程,有望改善疗效、促进纤维化消退、优化代谢结局并减少不良反应。

要点

  • 肝脏靶向联合如THR-β激动剂联合ACC抑制剂或PPAR激动剂旨在改善MASH组织学特征。
  • 系统代谢与肝脏特异药物联用如GLP-1受体激动剂联合FGF-21类似物或THR-β激动剂旨在优化体重、胰岛素抵抗和血脂。
  • 合理药物配对如DGAT2抑制剂联合ACC抑制剂或GLP-1/胰高血糖素受体双重激动剂可借互补机制改善安全性与耐受性。

核心结论

  • 多靶点联合治疗有望较单药更全面、持久地改善MASH肝脏病理和全身健康。

研究设计与样本

  • 本文为综述,整合MASH多靶点及联合治疗现有知识、机制原理和新兴临床证据。

主要发现

  • 单靶点单药常仅部分改善组织学肝纤维化和系统代谢参数。
  • 联合策略可调节多个互补致病过程,潜在提高疗效、促进纤维化消退、优化代谢结局并减少治疗相关不良反应。

关键数值与推荐

  • 肝脏靶向联合包括THR-β激动剂联合ACC抑制剂或过氧化物酶体增殖物激活受体激动剂,旨在改善MASH组织学特征。
  • 系统代谢与肝脏特异药物联用包括GLP-1受体激动剂联合FGF-21类似物或THR-β激动剂,旨在优化体重、胰岛素抵抗和血浆血脂。
  • 药物配对包括DGAT2抑制剂联合ACC抑制剂或GLP-1/胰高血糖素受体双重激动剂,可借互补机制减轻不良反应。

临床怎么用

  • 为临床医生和研究者提供优化MASH个体化管理、改善肝脏和全身结局的综合框架。
  • 关注以患者为中心的联合治疗实施中的实际问题。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Metabolic dysfunction-associated steatohepatitis (MASH) is a multifactorial metabolic liver disease that occurs in the context of obesity, insulin resistance and cardiometabolic comorbidities. Monotherapy targeting single pathways often provides only partial improvements in histological liver fibrosis and systemic metabolic parameters, prompting growing interest in multitargeted combination therapies. Multitargeted and combination strategies for MASH can modulate multiple and complementary pathogenic processes, potentially improving efficacy, promoting liver fibrosis regression, optimising systemic metabolic outcomes and reducing treatment-related adverse effects. Liver-directed combination therapies, such as thyroid hormone receptor-beta (THR-β) agonists along with acetyl-CoA carboxylase (ACC) inhibitors or peroxisome proliferator-activated receptor agonists, aim to improve histological features of MASH. Regimens combining systemic metabolic and liver-specific agents, such as glucagon-like peptide-1 (GLP-1) receptor agonists with fibroblast growth factor-21 analogues or THR-β agonists, aim to optimise metabolic outcomes, including body weight, insulin resistance and plasma lipids. Thoughtfully designed drug pairings, such as diacylglycerol O-acyltransferase 2 inhibitors combined with ACC inhibitors or GLP-1 and glucagon receptor dual agonists, could improve safety and tolerability by leveraging complementary mechanisms that may mitigate adverse effects. These therapeutic strategies aim to achieve more comprehensive and durable improvements in both liver pathology and systemic health than single-agent therapy alone. This review integrates current knowledge on multitargeted and combination therapies for MASH, examines mechanistic rationales and emerging clinical evidence and addresses practical considerations for patient-centred implementation. Therefore, we aim to provide clinicians and researchers with a comprehensive framework to optimise individualised management and improve both hepatic and systemic outcomes in individuals living with MASH.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Zhou XD, Fan QY, Byrne CD, et al. Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities. Gut. 2026. PMID: 41475978. doi:10.1136/gutjnl-2025-337431

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。